MBX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWMBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights

Nov 9, 2026

8-K

MBX Biosciences Appoints Peter Radovich to Board of Directors

Oct 22, 2026

8-K

MBX Biosciences Initiates Pivotal Phase 3 oPTimize Trial for Once-Weekly Canvuparatide in Hypoparathyroidism

Aug 27, 2026

8-K

MBX Biosciences Reports Second Quarter 2026 Financial Results and Pipeline Progress

Aug 6, 2026

8-K

MBX Biosciences Announces Executive Leadership Transition

Jul 13, 2026

8-K

MBX Biosciences Announces Positive One-Year Data for Once-Weekly Canvuparatide in Chronic Hypoparathyroidism

Jun 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

SHARE RESALE REGISTRATION | Shares amount: 11,108,055 | Share price: $18 | | Offering amount: $199,944,990

Sep 25, 2025

424B5

SHELF OFFERING | Shares amount: 10,200,000 | Share price: $16.00 | Offering amount: $163,200,000.00 | Bank: J.P. Morgan, Jefferies, Stifel, Guggenheim Securities

Sep 13, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

March 2026 SHELF + ATM

Mar 12, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2026

S-3

November 2025 SHELF & ATM

Nov 6, 2025

S-1MEF

SHARE RESALE REGISTRATION | Shares amount: 1,274,263 |

Sep 24, 2025

S-1

OFFERING

Sep 22, 2025

DRS

Form DRS - Draft Registration Statement

Aug 8, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 8, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Azoulay Salomon (Reporting)

Nov 5, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

Radovich Peter (Reporting)

Oct 22, 2026

Radovich Peter (Reporting)

Oct 22, 2026

144

Form 144 - Report of proposed sale of securities

Aug 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 9, 2025

CORRESP

Form CORRESP - Correspondence

Dec 4, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 25, 2025

CORRESP

Form CORRESP - Correspondence

Sep 22, 2025

CORRESP

Form CORRESP - Correspondence

Sep 22, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 13, 2025

MBX Biosciences, Inc. Common Stock MBX · SEC Filings